Review



lpxc recombinant protein  (MyBiosource Biotechnology)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MyBiosource Biotechnology lpxc recombinant protein
    MT reduces production of microbial LPS via inhibiting <t>LpxC</t> expression in E coli. ( A ) Growth curves of E coli under MT treatment with various dosages in vitro (1, 5, 10 mmol/L) (optical density 600 nm, n = 6). ( B ) Amount of E coli due to MT treatment with various dosages in vitro (1, 5, 10 mmol/L) (optical density 600 nm, n = 6). ( C ) Level of E coli LPS under MT treatment with various dosages in culture (1, 5, 10 mmol/L) (ng/mL, n = 6). ( D ) Regulatory circuit of E coli -derived LPS (references 64 and 66). ( E ) Relative mRNA levels of LpxC and FtsH in E coli (n = 4). ( F ) Level of E coli LPS under MT treatment (10 mmol/L) with/without LpxC <t>recombinant</t> protein (0.5 mmol/L) after 12 hours (ng/mL, n = 6) ( G ) Level of E coli LPS under various treatments including CHIR-090, CHIR-090+MT (10 mmol/L), meropenem, meropenem+MT (10 mmol/L) (ng/mL, n = 6). ( H ) Level of E coli LPS under co-culture with Akk muciniphila (ng/mL, n = 6). Values are means ± SEM. Same markup represented no significant difference between 2 groups ( P > .05); different markup represented significant difference ( P < .05) compared with the other groups. ∗ P < .05 compared with the other groups.
    Lpxc Recombinant Protein, supplied by MyBiosource Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lpxc+recombinant+protein/pmc08536535-270-34-37?v=MyBiosource+Biotechnology
    Average 90 stars, based on 1 article reviews
    lpxc recombinant protein - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "The Mechanism of Oral Melatonin Ameliorates Intestinal and Adipose Lipid Dysmetabolism Through Reducing Escherichia Coli -Derived Lipopolysaccharide"

    Article Title: The Mechanism of Oral Melatonin Ameliorates Intestinal and Adipose Lipid Dysmetabolism Through Reducing Escherichia Coli -Derived Lipopolysaccharide

    Journal: Cellular and Molecular Gastroenterology and Hepatology

    doi: 10.1016/j.jcmgh.2021.06.024

    MT reduces production of microbial LPS via inhibiting LpxC expression in E coli. ( A ) Growth curves of E coli under MT treatment with various dosages in vitro (1, 5, 10 mmol/L) (optical density 600 nm, n = 6). ( B ) Amount of E coli due to MT treatment with various dosages in vitro (1, 5, 10 mmol/L) (optical density 600 nm, n = 6). ( C ) Level of E coli LPS under MT treatment with various dosages in culture (1, 5, 10 mmol/L) (ng/mL, n = 6). ( D ) Regulatory circuit of E coli -derived LPS (references 64 and 66). ( E ) Relative mRNA levels of LpxC and FtsH in E coli (n = 4). ( F ) Level of E coli LPS under MT treatment (10 mmol/L) with/without LpxC recombinant protein (0.5 mmol/L) after 12 hours (ng/mL, n = 6) ( G ) Level of E coli LPS under various treatments including CHIR-090, CHIR-090+MT (10 mmol/L), meropenem, meropenem+MT (10 mmol/L) (ng/mL, n = 6). ( H ) Level of E coli LPS under co-culture with Akk muciniphila (ng/mL, n = 6). Values are means ± SEM. Same markup represented no significant difference between 2 groups ( P > .05); different markup represented significant difference ( P < .05) compared with the other groups. ∗ P < .05 compared with the other groups.
    Figure Legend Snippet: MT reduces production of microbial LPS via inhibiting LpxC expression in E coli. ( A ) Growth curves of E coli under MT treatment with various dosages in vitro (1, 5, 10 mmol/L) (optical density 600 nm, n = 6). ( B ) Amount of E coli due to MT treatment with various dosages in vitro (1, 5, 10 mmol/L) (optical density 600 nm, n = 6). ( C ) Level of E coli LPS under MT treatment with various dosages in culture (1, 5, 10 mmol/L) (ng/mL, n = 6). ( D ) Regulatory circuit of E coli -derived LPS (references 64 and 66). ( E ) Relative mRNA levels of LpxC and FtsH in E coli (n = 4). ( F ) Level of E coli LPS under MT treatment (10 mmol/L) with/without LpxC recombinant protein (0.5 mmol/L) after 12 hours (ng/mL, n = 6) ( G ) Level of E coli LPS under various treatments including CHIR-090, CHIR-090+MT (10 mmol/L), meropenem, meropenem+MT (10 mmol/L) (ng/mL, n = 6). ( H ) Level of E coli LPS under co-culture with Akk muciniphila (ng/mL, n = 6). Values are means ± SEM. Same markup represented no significant difference between 2 groups ( P > .05); different markup represented significant difference ( P < .05) compared with the other groups. ∗ P < .05 compared with the other groups.

    Techniques Used: Expressing, In Vitro, Derivative Assay, Recombinant, Co-Culture Assay



    Similar Products

    lpxc recombinant protein  (MyBiosource Biotechnology)
    90
    MyBiosource Biotechnology lpxc recombinant protein
    MT reduces production of microbial LPS via inhibiting <t>LpxC</t> expression in E coli. ( A ) Growth curves of E coli under MT treatment with various dosages in vitro (1, 5, 10 mmol/L) (optical density 600 nm, n = 6). ( B ) Amount of E coli due to MT treatment with various dosages in vitro (1, 5, 10 mmol/L) (optical density 600 nm, n = 6). ( C ) Level of E coli LPS under MT treatment with various dosages in culture (1, 5, 10 mmol/L) (ng/mL, n = 6). ( D ) Regulatory circuit of E coli -derived LPS (references 64 and 66). ( E ) Relative mRNA levels of LpxC and FtsH in E coli (n = 4). ( F ) Level of E coli LPS under MT treatment (10 mmol/L) with/without LpxC <t>recombinant</t> protein (0.5 mmol/L) after 12 hours (ng/mL, n = 6) ( G ) Level of E coli LPS under various treatments including CHIR-090, CHIR-090+MT (10 mmol/L), meropenem, meropenem+MT (10 mmol/L) (ng/mL, n = 6). ( H ) Level of E coli LPS under co-culture with Akk muciniphila (ng/mL, n = 6). Values are means ± SEM. Same markup represented no significant difference between 2 groups ( P > .05); different markup represented significant difference ( P < .05) compared with the other groups. ∗ P < .05 compared with the other groups.
    Lpxc Recombinant Protein, supplied by MyBiosource Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lpxc+recombinant+protein/pmc08536535-270-34-37?v=MyBiosource+Biotechnology
    Average 90 stars, based on 1 article reviews
    lpxc recombinant protein - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    MT reduces production of microbial LPS via inhibiting LpxC expression in E coli. ( A ) Growth curves of E coli under MT treatment with various dosages in vitro (1, 5, 10 mmol/L) (optical density 600 nm, n = 6). ( B ) Amount of E coli due to MT treatment with various dosages in vitro (1, 5, 10 mmol/L) (optical density 600 nm, n = 6). ( C ) Level of E coli LPS under MT treatment with various dosages in culture (1, 5, 10 mmol/L) (ng/mL, n = 6). ( D ) Regulatory circuit of E coli -derived LPS (references 64 and 66). ( E ) Relative mRNA levels of LpxC and FtsH in E coli (n = 4). ( F ) Level of E coli LPS under MT treatment (10 mmol/L) with/without LpxC recombinant protein (0.5 mmol/L) after 12 hours (ng/mL, n = 6) ( G ) Level of E coli LPS under various treatments including CHIR-090, CHIR-090+MT (10 mmol/L), meropenem, meropenem+MT (10 mmol/L) (ng/mL, n = 6). ( H ) Level of E coli LPS under co-culture with Akk muciniphila (ng/mL, n = 6). Values are means ± SEM. Same markup represented no significant difference between 2 groups ( P > .05); different markup represented significant difference ( P < .05) compared with the other groups. ∗ P < .05 compared with the other groups.

    Journal: Cellular and Molecular Gastroenterology and Hepatology

    Article Title: The Mechanism of Oral Melatonin Ameliorates Intestinal and Adipose Lipid Dysmetabolism Through Reducing Escherichia Coli -Derived Lipopolysaccharide

    doi: 10.1016/j.jcmgh.2021.06.024

    Figure Lengend Snippet: MT reduces production of microbial LPS via inhibiting LpxC expression in E coli. ( A ) Growth curves of E coli under MT treatment with various dosages in vitro (1, 5, 10 mmol/L) (optical density 600 nm, n = 6). ( B ) Amount of E coli due to MT treatment with various dosages in vitro (1, 5, 10 mmol/L) (optical density 600 nm, n = 6). ( C ) Level of E coli LPS under MT treatment with various dosages in culture (1, 5, 10 mmol/L) (ng/mL, n = 6). ( D ) Regulatory circuit of E coli -derived LPS (references 64 and 66). ( E ) Relative mRNA levels of LpxC and FtsH in E coli (n = 4). ( F ) Level of E coli LPS under MT treatment (10 mmol/L) with/without LpxC recombinant protein (0.5 mmol/L) after 12 hours (ng/mL, n = 6) ( G ) Level of E coli LPS under various treatments including CHIR-090, CHIR-090+MT (10 mmol/L), meropenem, meropenem+MT (10 mmol/L) (ng/mL, n = 6). ( H ) Level of E coli LPS under co-culture with Akk muciniphila (ng/mL, n = 6). Values are means ± SEM. Same markup represented no significant difference between 2 groups ( P > .05); different markup represented significant difference ( P < .05) compared with the other groups. ∗ P < .05 compared with the other groups.

    Article Snippet: The abundance of E coli was determined through using optical density at 600 nm, and the levels of E coli -derived LPS were measured using optical density at 450 nm in various treatments, including LpxC recombinant protein (MyBioSource, San Diego, CA), CHIR-090 (MedChemExpress, Shanghai, China), meropenem and butyrate (Sigma-Aldrich).

    Techniques: Expressing, In Vitro, Derivative Assay, Recombinant, Co-Culture Assay